Page last updated: 2024-09-05

erlotinib hydrochloride and 3,3'-diindolylmethane

erlotinib hydrochloride has been researched along with 3,3'-diindolylmethane in 2 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (3,3'-diindolylmethane)	Trials (3,3'-diindolylmethane)	Recent Studies (post-2010) (3,3'-diindolylmethane)
4,353	786	3,033	409	16	252

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH	1
Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH; Schaffert, JM	1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and 3,3'-diindolylmethane

Article	Year
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Molecular cancer therapeutics, 2008, Volume: 7, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence; Humans; Indoles; Mice; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays	2008
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. Journal of cellular biochemistry, 2010, Volume: 110, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays	2010

Article

Year

Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.

Molecular cancer therapeutics, 2008, Volume: 7, Issue:6

Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence; Humans; Indoles; Mice; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2008

Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.

Journal of cellular biochemistry, 2010, Volume: 110, Issue:1

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2010